[27] Alix-Panabieres C,

Schwarzenbach H, Lantel K. Circulating tumor cells and circulating tumor DNA. Annual Review Medicine. 2012;**63**: 199-215. [A review discussing the detection, characterization, and diagnostic implications of rare circulating tumor cells and free nucleic acids derived from tumors]

[28] Kohlmann A, Grossmann V, Haferlach T. Integration of next-generation sequencing into clinical practice: Are we there yet? Seminars in Oncology. 2012;**39**:26-36. [A discussion of how and when deep sequencing may impact cancer diagnosis, therapy selection, and monitoring of response to therapy]

[29] Pao W, Lafrate AJ, Su Z. Genetically informed lung cancer medicine. Pathology. 2011;**223**:230-240. [A review of the rapid adoption and application of genomic analysis to the diagnosis and treatment of lung cancer]

[30] Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Current Opinion in Rheumatology. 2013;**25**: 44-49. [A review focused on paraneoplastic sunovitis, bone disease, myositis, and vasculitis]

[31] Graus F, Dalmau I. Paraneoplastic neurological syndromes. Current

Opinion in Neurology. 2012;**25**:795-801. [A review describing parancoplastic neurological syndromes and the impact of antibodies against surface antigens in their management]

[32] Lucia S, Esposito M, Rossi Fanelli F, et al. Cancer cachexia: From molecular mechanisms to patient's care. Critical Review Oncogology. 2012;**17**:315-321. [A review of cancer cachexia mechanisms and their implications for development of effective therapies]

#### **Chapter 8**
